IVA stock forecast, quote, news & analysis
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH... Show more
Why Is Inventiva S.A. (IVA) Stock Down -15.93% Today?
Key Takeaways
- Inventiva S.A. (IVA) shares fell approximately 15.93% from the prior session close of $4.77 to a latest available price of $4.01.
- The primary catalyst was a temporary trading halt on Euronext Paris ahead of a proposed financing transaction, with trading resuming later in the session.
- Secondary factors included analyst price target reductions tied to financing concerns and broader biotech sector sentiment.
- Volume was elevated compared with recent averages, reflecting heightened investor reaction to the corporate announcement.
- Traders are now watching for details on the financing terms and any impact on the company’s cash runway ahead of its Phase 3 MASH trial readout.
Opening Summary
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs. On June 2, 2026, IVA shares declined sharply, closing or last trading at $4.01 after the previous session’s close of $4.77. The move represented a decline of 15.93%. Markets attributed the drop primarily to uncertainty surrounding a proposed financing transaction that prompted a temporary halt in trading of the company’s ordinary shares on Euronext Paris.
Financing Announcement and Trading Halt
Inventiva requested a temporary suspension of trading on Euronext Paris effective at the market open on June 2, 2026, citing preparations for a proposed financing transaction. Trading was expected to resume later that day once ADSs began trading on Nasdaq. The announcement created immediate uncertainty among investors regarding potential share dilution, prompting selling pressure once trading resumed.
Analyst Reactions and Sector Context
Recent analyst commentary had already highlighted financing-related risks. Guggenheim lowered its price target on IVA in connection with financing developments, while other firms maintained Buy ratings but noted the need for additional capital ahead of key clinical milestones. The broader biotech sector showed mixed performance, with some peers also sensitive to capital-raising news amid ongoing clinical development timelines.
Market Context and Trading Activity
Trading volume in IVA was notably higher than recent daily averages, indicating strong participation around the corporate update. The price action diverged from major indices, which traded relatively flat to modestly lower. Technical levels were breached as the stock moved below recent support areas established in prior sessions.
Trending AI Robots
Trending AI Robots is Tickeron’s curated section highlighting the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered trading bots across thousands of tickers, with strategies varying by time frame, risk parameters, and performance metrics. Only bots demonstrating robust results in prevailing conditions are featured. Explore the full selection and performance data on the Trending AI Robots page.
What Comes Next for IVA
Investors will monitor the release of additional details on the proposed financing transaction and any resulting impact on the company’s capital structure. Upcoming catalysts include further updates on the Phase 3 NATiV3 trial for lanifibranor in MASH, as well as quarterly financial reporting. Risks remain around clinical timelines, regulatory outcomes, and ongoing capital requirements typical for clinical-stage biopharmaceutical companies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IVA sees MACD Histogram crosses below signal line
IVA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on May 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 37 instances where the indicator turned negative. In of the 37 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVA as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
IVA moved below its 50-day moving average on May 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for IVA moved below the 200-day moving average on June 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IVA entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.059). P/E Ratio (0.000) is within average values for comparable stocks, (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). IVA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (128.205) is also within normal values, averaging (361.315).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases
Industry Biotechnology